New cancer drug shows promise in early human trials

NCT ID NCT03994601

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested a new drug called BMS-986288, both by itself and combined with an existing immunotherapy (nivolumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe doses and see if the treatments could shrink tumors. The study involved 219 participants and was designed to gather initial safety and effectiveness data.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Centre Hospitalier intercommunal de Toulon La Seyne sur Mer

Toulon, 83100, France
Local Institution - 0001

Hackensack, New Jersey, 07601, United States
Local Institution - 0002

Baltimore, Maryland, 21287, United States
Local Institution - 0004

St Louis, Missouri, 63110, United States
Local Institution - 0005

Aurora, Colorado, 80045, United States
Local Institution - 0006

Toronto, Ontario, M5G 2M9, Canada
Local Institution - 0008

ABB, Distrito Federal, C1199, Argentina
Local Institution - 0009

Santiago, Santiago Metropolitan, 8420383, Chile
Local Institution - 0010

Viña del Mar, Región de Valparaíso, 2520598, Chile
Local Institution - 0011

Ciudad Autónoma de Buenos Aires, Buenos Aires, 1426, Argentina
Local Institution - 0012

CABA, Distrito Federal, C1430, Argentina
Local Institution - 0013

Río Cuarto, Córdoba Province, 5800, Argentina
Local Institution - 0014

Córdoba, Córdoba Province, X5000HXL, Argentina
Local Institution - 0015

Paris, 75248, France
Local Institution - 0016

Buenos Aires, C1280AEB, Argentina
Local Institution - 0017

Buenos Aires, 1431, Argentina
Local Institution - 0018

Bron, 69677, France
Local Institution - 0019

Santiago, Santiago Metropolitan, 7510032, Chile
Local Institution - 0022

Saint-Herblain, Loire-Atlantique, 44800, France
Local Institution - 0023

Madrid, 28041, Spain
Local Institution - 0024

Majadahonda, 28222, Spain
Local Institution - 0025

Valencia, 46026, Spain
Local Institution - 0026

Marseille, 13915, France
Local Institution - 0028

Ancona, 60126, Italy
Local Institution - 0031

Milan, 20162, Italy
Local Institution - 0033

Catanzaro, 88100, Italy
Local Institution - 0034

Bordeaux, Gironde, 33075, France
Local Institution - 0035

Santiago, Santiago Metropolitan, 7620002, Chile
Local Institution - 0036

Santiago, Santiago Metropolitan, 7500921, Chile
Local Institution - 0038

Padua, Veneto, 35128, Italy
Local Institution - 0039

Roma, 00168, Italy
Local Institution - 0040

Milan, Lombardy, 20133, Italy
Local Institution - 0042

Montreal, Quebec, H2X 0A9, Canada
Local Institution - 0046

Montreal, Quebec, H3T 1E2, Canada
Local Institution - 0050

Orange, California, 92868-3201, United States
Local Institution - 0054

Barcelona, Catalunya [Cataluña], 08036, Spain
Local Institution - 0055

Seville, 41013, Spain
Local Institution - 0056

Barcelona, Barcelona [Barcelona], 08035, Spain
Local Institution - 0074

Buenos Aires, Buenos Aires F.D., C1096AAS, Argentina
Local Institution - 0075

Costa Mesa, California, 92627, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED CANCER